BK Polyomavirus Viremia Clearance by Month 4 and Enzyme-linked Immune Absorbent Spot Results
| Participant . | Month 1 Viremia Copies/mL . | Month 2 Viremia Copies/mL . | Month 3 Viremia Copies/mL . | Month 3 ELISPOT Spots Above Control . | Month 4 Viremia Copies/mL . |
|---|---|---|---|---|---|
| Cleared viremia | |||||
| 1 | 2000 | 7600 | 3400 | 0 | 0 |
| 2 | 417 | 168 | 0 | 2.9 | 0 |
| 3 | 1200 | 51 | 0 | 20.4 | 0 |
| 4 | 3000 | 500 | 0 | 149 | 0 |
| 5 | 0 | 6800 | 196 | 7 | 0 |
| 6 | 190 | 5300 | 600 | 65.7 | 0 |
| 7 | 0 | 1100 | 900 | 44.3 | 0 |
| 8 | 38 | 102 | 0 | 3.3 | 0 |
| 9 | 700 | 172 | 0 | 1.7 | 0 |
| 10 | 5900 | 11 900 | 8700 | 0 | 0 |
| 11 | No sample | 201 | 185 | 1.9 | 0 |
| 12 | 1 300 000 | 58 700 | 98 | 127.3 | 0 |
| 13 | 0 | 2900 | 148 | 82.5 | 0 |
| 14 | 2400 | 2100 | 0 | 48.5 | 0 |
| 15 | 4200 | 1500 | 0 | 38.2 | 0 |
| 16 | 16 100 | 316 | 0 | 26.3 | 0 |
| 17 | 67 | 1600 | 1100 | 19.8 | 0 |
| 18 | 1300 | 70 | 0 | 14.3 | 0 |
| Did not clear viremia | |||||
| 1 | 175 | 1200 | 0 | 0 | 89 |
| 2 | 1400 | 26 500 | 10 400 | 8.4 | 109 |
| 3 | 1300 | 7200 | 900 | 153.6 | 193 |
| 4 | 900 | 500 | 429 | 14.5 | 800 |
| 5 | 0 | 1400 | 339 | 2.1 | 1000 |
| 6 | 1100 | 23 300 | 42 500 | 0 | 2700 |
| 7 | 1700 | 600 | 700 | 1.6 | 2800 |
| 8 | 900 | 2100 | 66 400 | 0 | 2900 |
| 9 | 38 | No sample | 35 000 | 0 | 3100 |
| 10 | 800 | 700 | 1700 | 17.4 | 3300 |
| 11 | 1700 | 57 500 | 166 000 | .8 | 3600 |
| 12 | 6400 | 60 000 | 800 | 40.3 | 4000 |
| 13 | 3000 | 900 | 7300 | 0 | 5500 |
| 14 | 222 | 1300 | 5700 | 0 | 6700 |
| 15 | 1500 | 12 900 | 93 000 | 1.3 | 13 500 |
| 16 | 209 | 3900 | 16 400 | 0 | 23 500 |
| 17 | 4700 | 8500 | 27 800 | −3.8 | 34 500 |
| 18 | 900 | 21 600 | 48 800 | 4.1 | 57 400 |
| 19 | 600 | 3600 | 25 700 | 1.2 | 68 900 |
| 20 | 800 | 1100 | 1900 | −1.7 | 97 000 |
| 21 | 184 000 | 496 000 | 2 000 000 | 5.9 | 460 000 |
| 22 | No sample | 574 000 | 682 000 | −1.3 | 463 000 |
| 23 | 79 900 | 2 700 000 | 8 500 000 | 8.2 | 1 400 000 |
| 24 | 87 | 73 000 | 168 000 | 22.3 | 2 400 000 |
| 25 | 26 100 | 287 000 | 14 000 000 | 64.9 | 13 000 000 |
| Participant . | Month 1 Viremia Copies/mL . | Month 2 Viremia Copies/mL . | Month 3 Viremia Copies/mL . | Month 3 ELISPOT Spots Above Control . | Month 4 Viremia Copies/mL . |
|---|---|---|---|---|---|
| Cleared viremia | |||||
| 1 | 2000 | 7600 | 3400 | 0 | 0 |
| 2 | 417 | 168 | 0 | 2.9 | 0 |
| 3 | 1200 | 51 | 0 | 20.4 | 0 |
| 4 | 3000 | 500 | 0 | 149 | 0 |
| 5 | 0 | 6800 | 196 | 7 | 0 |
| 6 | 190 | 5300 | 600 | 65.7 | 0 |
| 7 | 0 | 1100 | 900 | 44.3 | 0 |
| 8 | 38 | 102 | 0 | 3.3 | 0 |
| 9 | 700 | 172 | 0 | 1.7 | 0 |
| 10 | 5900 | 11 900 | 8700 | 0 | 0 |
| 11 | No sample | 201 | 185 | 1.9 | 0 |
| 12 | 1 300 000 | 58 700 | 98 | 127.3 | 0 |
| 13 | 0 | 2900 | 148 | 82.5 | 0 |
| 14 | 2400 | 2100 | 0 | 48.5 | 0 |
| 15 | 4200 | 1500 | 0 | 38.2 | 0 |
| 16 | 16 100 | 316 | 0 | 26.3 | 0 |
| 17 | 67 | 1600 | 1100 | 19.8 | 0 |
| 18 | 1300 | 70 | 0 | 14.3 | 0 |
| Did not clear viremia | |||||
| 1 | 175 | 1200 | 0 | 0 | 89 |
| 2 | 1400 | 26 500 | 10 400 | 8.4 | 109 |
| 3 | 1300 | 7200 | 900 | 153.6 | 193 |
| 4 | 900 | 500 | 429 | 14.5 | 800 |
| 5 | 0 | 1400 | 339 | 2.1 | 1000 |
| 6 | 1100 | 23 300 | 42 500 | 0 | 2700 |
| 7 | 1700 | 600 | 700 | 1.6 | 2800 |
| 8 | 900 | 2100 | 66 400 | 0 | 2900 |
| 9 | 38 | No sample | 35 000 | 0 | 3100 |
| 10 | 800 | 700 | 1700 | 17.4 | 3300 |
| 11 | 1700 | 57 500 | 166 000 | .8 | 3600 |
| 12 | 6400 | 60 000 | 800 | 40.3 | 4000 |
| 13 | 3000 | 900 | 7300 | 0 | 5500 |
| 14 | 222 | 1300 | 5700 | 0 | 6700 |
| 15 | 1500 | 12 900 | 93 000 | 1.3 | 13 500 |
| 16 | 209 | 3900 | 16 400 | 0 | 23 500 |
| 17 | 4700 | 8500 | 27 800 | −3.8 | 34 500 |
| 18 | 900 | 21 600 | 48 800 | 4.1 | 57 400 |
| 19 | 600 | 3600 | 25 700 | 1.2 | 68 900 |
| 20 | 800 | 1100 | 1900 | −1.7 | 97 000 |
| 21 | 184 000 | 496 000 | 2 000 000 | 5.9 | 460 000 |
| 22 | No sample | 574 000 | 682 000 | −1.3 | 463 000 |
| 23 | 79 900 | 2 700 000 | 8 500 000 | 8.2 | 1 400 000 |
| 24 | 87 | 73 000 | 168 000 | 22.3 | 2 400 000 |
| 25 | 26 100 | 287 000 | 14 000 000 | 64.9 | 13 000 000 |
These 43 selected participants had persistent viremia in the first 3 months after transplant, had a Month 4 sample to assess for clearance, and had a Month 3 ELISPOT result. Participants with peak viremia <10 000 copies/mL and ELISPOT counts >10 above the negative control (bold and highlighted) were more likely to clear viremia by Month 4.
Abbreviation: ELISPOT, enzyme-linked immune absorbent spot.
BK Polyomavirus Viremia Clearance by Month 4 and Enzyme-linked Immune Absorbent Spot Results
| Participant . | Month 1 Viremia Copies/mL . | Month 2 Viremia Copies/mL . | Month 3 Viremia Copies/mL . | Month 3 ELISPOT Spots Above Control . | Month 4 Viremia Copies/mL . |
|---|---|---|---|---|---|
| Cleared viremia | |||||
| 1 | 2000 | 7600 | 3400 | 0 | 0 |
| 2 | 417 | 168 | 0 | 2.9 | 0 |
| 3 | 1200 | 51 | 0 | 20.4 | 0 |
| 4 | 3000 | 500 | 0 | 149 | 0 |
| 5 | 0 | 6800 | 196 | 7 | 0 |
| 6 | 190 | 5300 | 600 | 65.7 | 0 |
| 7 | 0 | 1100 | 900 | 44.3 | 0 |
| 8 | 38 | 102 | 0 | 3.3 | 0 |
| 9 | 700 | 172 | 0 | 1.7 | 0 |
| 10 | 5900 | 11 900 | 8700 | 0 | 0 |
| 11 | No sample | 201 | 185 | 1.9 | 0 |
| 12 | 1 300 000 | 58 700 | 98 | 127.3 | 0 |
| 13 | 0 | 2900 | 148 | 82.5 | 0 |
| 14 | 2400 | 2100 | 0 | 48.5 | 0 |
| 15 | 4200 | 1500 | 0 | 38.2 | 0 |
| 16 | 16 100 | 316 | 0 | 26.3 | 0 |
| 17 | 67 | 1600 | 1100 | 19.8 | 0 |
| 18 | 1300 | 70 | 0 | 14.3 | 0 |
| Did not clear viremia | |||||
| 1 | 175 | 1200 | 0 | 0 | 89 |
| 2 | 1400 | 26 500 | 10 400 | 8.4 | 109 |
| 3 | 1300 | 7200 | 900 | 153.6 | 193 |
| 4 | 900 | 500 | 429 | 14.5 | 800 |
| 5 | 0 | 1400 | 339 | 2.1 | 1000 |
| 6 | 1100 | 23 300 | 42 500 | 0 | 2700 |
| 7 | 1700 | 600 | 700 | 1.6 | 2800 |
| 8 | 900 | 2100 | 66 400 | 0 | 2900 |
| 9 | 38 | No sample | 35 000 | 0 | 3100 |
| 10 | 800 | 700 | 1700 | 17.4 | 3300 |
| 11 | 1700 | 57 500 | 166 000 | .8 | 3600 |
| 12 | 6400 | 60 000 | 800 | 40.3 | 4000 |
| 13 | 3000 | 900 | 7300 | 0 | 5500 |
| 14 | 222 | 1300 | 5700 | 0 | 6700 |
| 15 | 1500 | 12 900 | 93 000 | 1.3 | 13 500 |
| 16 | 209 | 3900 | 16 400 | 0 | 23 500 |
| 17 | 4700 | 8500 | 27 800 | −3.8 | 34 500 |
| 18 | 900 | 21 600 | 48 800 | 4.1 | 57 400 |
| 19 | 600 | 3600 | 25 700 | 1.2 | 68 900 |
| 20 | 800 | 1100 | 1900 | −1.7 | 97 000 |
| 21 | 184 000 | 496 000 | 2 000 000 | 5.9 | 460 000 |
| 22 | No sample | 574 000 | 682 000 | −1.3 | 463 000 |
| 23 | 79 900 | 2 700 000 | 8 500 000 | 8.2 | 1 400 000 |
| 24 | 87 | 73 000 | 168 000 | 22.3 | 2 400 000 |
| 25 | 26 100 | 287 000 | 14 000 000 | 64.9 | 13 000 000 |
| Participant . | Month 1 Viremia Copies/mL . | Month 2 Viremia Copies/mL . | Month 3 Viremia Copies/mL . | Month 3 ELISPOT Spots Above Control . | Month 4 Viremia Copies/mL . |
|---|---|---|---|---|---|
| Cleared viremia | |||||
| 1 | 2000 | 7600 | 3400 | 0 | 0 |
| 2 | 417 | 168 | 0 | 2.9 | 0 |
| 3 | 1200 | 51 | 0 | 20.4 | 0 |
| 4 | 3000 | 500 | 0 | 149 | 0 |
| 5 | 0 | 6800 | 196 | 7 | 0 |
| 6 | 190 | 5300 | 600 | 65.7 | 0 |
| 7 | 0 | 1100 | 900 | 44.3 | 0 |
| 8 | 38 | 102 | 0 | 3.3 | 0 |
| 9 | 700 | 172 | 0 | 1.7 | 0 |
| 10 | 5900 | 11 900 | 8700 | 0 | 0 |
| 11 | No sample | 201 | 185 | 1.9 | 0 |
| 12 | 1 300 000 | 58 700 | 98 | 127.3 | 0 |
| 13 | 0 | 2900 | 148 | 82.5 | 0 |
| 14 | 2400 | 2100 | 0 | 48.5 | 0 |
| 15 | 4200 | 1500 | 0 | 38.2 | 0 |
| 16 | 16 100 | 316 | 0 | 26.3 | 0 |
| 17 | 67 | 1600 | 1100 | 19.8 | 0 |
| 18 | 1300 | 70 | 0 | 14.3 | 0 |
| Did not clear viremia | |||||
| 1 | 175 | 1200 | 0 | 0 | 89 |
| 2 | 1400 | 26 500 | 10 400 | 8.4 | 109 |
| 3 | 1300 | 7200 | 900 | 153.6 | 193 |
| 4 | 900 | 500 | 429 | 14.5 | 800 |
| 5 | 0 | 1400 | 339 | 2.1 | 1000 |
| 6 | 1100 | 23 300 | 42 500 | 0 | 2700 |
| 7 | 1700 | 600 | 700 | 1.6 | 2800 |
| 8 | 900 | 2100 | 66 400 | 0 | 2900 |
| 9 | 38 | No sample | 35 000 | 0 | 3100 |
| 10 | 800 | 700 | 1700 | 17.4 | 3300 |
| 11 | 1700 | 57 500 | 166 000 | .8 | 3600 |
| 12 | 6400 | 60 000 | 800 | 40.3 | 4000 |
| 13 | 3000 | 900 | 7300 | 0 | 5500 |
| 14 | 222 | 1300 | 5700 | 0 | 6700 |
| 15 | 1500 | 12 900 | 93 000 | 1.3 | 13 500 |
| 16 | 209 | 3900 | 16 400 | 0 | 23 500 |
| 17 | 4700 | 8500 | 27 800 | −3.8 | 34 500 |
| 18 | 900 | 21 600 | 48 800 | 4.1 | 57 400 |
| 19 | 600 | 3600 | 25 700 | 1.2 | 68 900 |
| 20 | 800 | 1100 | 1900 | −1.7 | 97 000 |
| 21 | 184 000 | 496 000 | 2 000 000 | 5.9 | 460 000 |
| 22 | No sample | 574 000 | 682 000 | −1.3 | 463 000 |
| 23 | 79 900 | 2 700 000 | 8 500 000 | 8.2 | 1 400 000 |
| 24 | 87 | 73 000 | 168 000 | 22.3 | 2 400 000 |
| 25 | 26 100 | 287 000 | 14 000 000 | 64.9 | 13 000 000 |
These 43 selected participants had persistent viremia in the first 3 months after transplant, had a Month 4 sample to assess for clearance, and had a Month 3 ELISPOT result. Participants with peak viremia <10 000 copies/mL and ELISPOT counts >10 above the negative control (bold and highlighted) were more likely to clear viremia by Month 4.
Abbreviation: ELISPOT, enzyme-linked immune absorbent spot.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
